Time to active sitting position: One-year findings from a temporary COVID-19 intensive care unit.

Authors:
Rossi V; Del Monaco C; Gambazza S; Santambrogio M; Binda F and 6 more

Journal:
Respir Med

Publication Year: 2022

DOI:
10.1016/j.rmed.2022.106773

PMCID:
PMC8843323

PMID:
35203010

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Respir Med

Abbreviation: Respir Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pulmonary Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Analysis of inflammatory protein profiles in the circulation of COVID-19 patients identifies patien…
Keur N; Saridaki M; Ricaño-Ponce I and 3 more (2023) - Transparency Score: 4/6
Lung parenchymal abnormalities and outcomes in hospitalized patients with COVID 19 pneumonia: A pos…
Datta B; Prakash AK; Yaddanapudi K and 7 more (2023) - Transparency Score: 3/6
Lung ultrasound as a tool for monitoring the interstitial changes in recently hospitalised patients…
Loke TK; Earl N; Begbey ACH and 7 more (2023) - Transparency Score: 3/6
Multiple manifestations of uncontrolled asthma increase the risk of severe COVID-19.
Selberg S; Karlsson Sundbaum J; Konradsen JR and 4 more (2023) - Transparency Score: 3/6
Pneumothorax in hospitalized COVID-19 patients with severe respiratory failure: Risk factors and ou…
Ragnoli B; Cena T; Radaeli A and 5 more (2023) - Transparency Score: 1/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Francesco Blasi reports financial support was provided by Pfizer Inc. Francesco Blasi reports financial support was provided by AstraZeneca Pharmaceuticals LP. Francesco Blasi reports financial support was provided by Chiesi Pharmaceuticals Inc. Francesco Blasi reports financial support was provided by Insmed Inc. Francesco Blasi reports financial support was provided by Menarini Research. Francesco Blasi reports financial support was provided by GSK. Francesco Blasi reports financial support was provided by Guidotti Laboratories. Francesco Blasi reports financial support was provided by Novartis. Francesco Blasi reports financial support was provided by Viatris Inc. Francesco Blasi reports financial support was provided by Vertex Pharmaceuticals. Francesco Blasi reports financial support was provided by Zambon Pharmaceutical Laboratories."

Evidence found in paper:

"The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Francesco Blasi reports financial support was provided by Pfizer Inc. Francesco Blasi reports financial support was provided by AstraZeneca Pharmaceuticals LP. Francesco Blasi reports financial support was provided by Chiesi Pharmaceuticals Inc. Francesco Blasi reports financial support was provided by Insmed Inc. Francesco Blasi reports financial support was provided by Menarini Research. Francesco Blasi reports financial support was provided by GSK. Francesco Blasi reports financial support was provided by Guidotti Laboratories. Francesco Blasi reports financial support was provided by Novartis. Francesco Blasi reports financial support was provided by Viatris Inc. Francesco Blasi reports financial support was provided by Vertex Pharmaceuticals. Francesco Blasi reports financial support was provided by Zambon Pharmaceutical Laboratories."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025